GLPG4399 / Galapagos, Gilead - LARVOL DELTA

Assessing Drug Product Shelf Life Using the Accelerated Stability Assessment Program: A Case Study of a GLPG4399 Capsule Formulation. (PubMed, Pharmaceutics) - " We demonstrated the application of the ASAP approach to evaluate the shelf life of a GLPG4399 solid capsule formulation. The studied ASAP approach can be extended to evaluate the stability and shelf-life estimations of other early-phase clinical formulations."

Journal

GLPG4399: selective SIK3 inhibition as a novel mode of action for the treatment of inflammatory arthritic diseases (preclinical) (EULAR 2022) - "Our preclinical findings demonstrate the strong immunomodulatory effect of SIK3 inhibition in arthritis-relevant inflammatory cell assays and highlight the significant preclinical efficacy of GLPG4399 in two experimental arthritis mouse models. The novel mechanisms of action of GLPG4399 represents a promising approach for the treatment of arthritis."

Preclinical • Immune Modulation • Inflammatory Arthritis • Oncology • Psoriatic Arthritis • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL23A • TNFA

A Study to Evaluate How Well Single and Multiple Doses of GLPG4399 Are Tolerated in Healthy, Adult Subjects (clinicaltrials.gov) - P1 | N=88 | Completed | Sponsor: Galapagos NV | Recruiting ➔ Completed

Trial completion